Assessing XtalPi Holdings (SEHK:2228) Rich Valuation After Strong Growth And Recent Share Price Pullback

Recent share performance and business snapshot

XtalPi Holdings (SEHK:2228) has drawn attention after a mixed period for the stock, with the share price down 4.2% on the day and lower over the past month and past 3 months.

For context, the company reports HK$802.623 million in revenue and HK$123.747 million in net income, with annual revenue growth of 26.38% and net income growth of 62.44%, and a market cap of about HK$35.46b.

See our latest analysis for XtalPi Holdings.

At a HK$8.24 share price, XtalPi Holdings has seen short term momentum fade, with the share price return down 13.54% over 30 days. However, the 1 year total shareholder return of 79.13% still reflects a strong overall gain.

If you are comparing XtalPi with other AI focused healthcare and drug discovery businesses, it can help to broaden the view using a curated list of 132 healthcare AI stocks

With both revenue and net income growing at double-digit rates, and the stock still trading below the HK$11.45 analyst price target, the key question is whether there is real value here or if the market is already pricing in future growth.

Preferred Price-to-Sales Multiple of 38.1x: Is it justified?

On the latest figures, XtalPi Holdings trades on a P/S of 38.1x, which sets a high bar given the HK$8.24 share price and current revenue base.

The P/S multiple compares the company’s market value with its annual revenue. This can be useful for businesses where earnings are still settling after a recent move into profitability. For XtalPi Holdings, this aligns with a profile where the company has only recently become profitable and where revenue growth expectations feature heavily in how the stock is being valued.

What stands out is how far this multiple sits above benchmarks. The current 38.1x P/S is more than double the peer average of 18.4x, and much higher than the Asian Life Sciences industry average of 4.4x. Relative to the estimated fair P/S of 10.8x, the market is assigning a significantly richer revenue multiple that could move closer to that fair level if sentiment or growth expectations change.

Explore the SWS fair ratio for XtalPi Holdings

Result: Price-to-Sales of 38.1x (OVERVALUED)

However, investors still need to weigh the high 38.1x P/S against execution risks in early stage drug discovery and the reliance on a relatively concentrated revenue base.

Find out about the key risks to this XtalPi Holdings narrative.

Next Steps

With growth, valuation and risk all pulling in different directions, it can help to look under the hood quickly and decide where you stand. To see how the positives and concerns balance out in one place, review the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If XtalPi already sits on your watchlist, do not stop there. Some of the most interesting opportunities appear when you compare it with different types of stocks side by side.

• Hunt for potential mispricings by scanning a curated set of 209 high quality undervalued stocks that pair quality fundamentals with appealing valuations.
• Prioritise resilience by reviewing 295 resilient stocks with low risk scores that score well on financial strength and business risk metrics.
• Get ahead of the crowd by searching a screener containing 516 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com